Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow GMAB by emailGet an email when GMAB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GMAB, unsubscribe in one click. Privacy
📣 What GMAB Says Is Next
during 2026 · “The financial guidance assumes that no significant new agreements are entered into during 2026 that could materially affect the results.”
Company press release, Aug 6, 2026 · SEC filing
in 2027 · “Based on this successful track record in late-stage development and excellence in commercial execution, Genmab expects to launch petosemtamab in 2027, subject to clinical results and receipt of regulatory approvals.”
Company press release, Dec 12, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full GMAB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GMAB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.